# DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines

> **NIH NIH N43** · MOLECULAR EXPRESS, INC. · 2023 · $599,925

## Abstract

The contractor will generate analogues of signal modifiers and co-formulate them with monophosphoryl lipid A using the contractor’s proprietary VesiVax liposomal system.

## Key facts

- **NIH application ID:** 10933265
- **Project number:** 75N93023C00033-0-9999-1
- **Recipient organization:** MOLECULAR EXPRESS, INC.
- **Principal Investigator:** SAM ONHO
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $599,925
- **Award type:** —
- **Project period:** 2023-09-30 → 2025-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10933265

## Citation

> US National Institutes of Health, RePORTER application 10933265, DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines (75N93023C00033-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10933265. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*